Agomelatine

Active ingredient description

Agomelatine is a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist. In humans, agomelatine has positive phase shifting properties; it induces a phase advance of sleep, body temperature decline and melatonin onset.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
N06AX22
Agomelatine
N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AX Other antidepressants
Discover more medicines within N06AX22

Medicines

$substanceName is the active ingredient of these drugs:

Drug
Countries
AGLONEX

Spain

AGODEPRIN

Estonia Lithuania Poland

AGOLEK

Poland

AGOMAVAL

Germany

LAMEGOM

Estonia Lithuania Poland

MELINOR

South Africa

SEDIVAL

Poland

SYMAGO

Poland

THYMANAX

Austria Estonia Ireland Lithuania Poland

TIMALIUM

South Africa

UNBREMI

Poland

VALDOXAN

Austria Brazil Cyprus Ecuador Estonia

VALDOXANE

South Africa

ZILBEA

Austria Estonia Lithuania

$substanceName is also found within below combination drugs:

AGOGEROLAN , AGOMELATIN

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
VALDOXAN Film-coated tablets
Summary of Product Characteristics (SPC)

Structural formula

Graphic representation of the active ingredient's molecular structure

Molecular mass: 243.301 g/mol

External identifiers

CAS Substance: 138112-76-2
DrugBank Drug: DB06594
KEGG Drug: D02578
SNOMED-CT Concept: 698012009
Agomelatine (substance)
UNII Identifier: 137R1N49AD
AGOMELATINE
 
Next: Usage >